Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 512-2 is a member of the miRNA family, functioning as a noncoding single-stranded RNA molecule typically 21–24 nucleotides in length. It is transcribed as a primary miRNA (pri-miRNA) and processed via the canonical miRNA pathway involving Drosha and Dicer RNases, Exportin-5, and Argonaute proteins. The mature miRNA is loaded into the RNA-induced silencing complex (RISC), where it binds to partially complementary sequences in the 3′ UTR of target mRNAs, generally using a 6-8 nucleotide seed region for target recognition. This results in translational repression or mRNA destabilization. miR-512-2, like other miRNAs, is involved in diverse cellular processes such as cell development, proliferation, differentiation, apoptosis, and disease, especially cancer. Individual miRNAs, including miR-512-2, can regulate hundreds of target genes and have broad regulatory effects within cells. Modulation of miRNAs is being explored therapeutically, but specificity and biological complexity remain significant challenges. No drugs targeting miR-512-2 are identified in current literature, nor are established biomarkers or companion diagnostics, but miRNAs as a class are under active investigation for diagnostic and therapeutic applications—especially in oncology. Safety concerns chiefly relate to unintended effects due to extensive multi-gene regulatory networks and potential disruption of normal cellular processes. If you need more detail about specific gene targets, validated disease associations, or experimental data for miR-512-2, more targeted literature or database queries (e.g., miRBase, PubMed, GeneCards) would be required.
microRNA-mRNA interaction (seed-dependent pairing resulting in target mRNA translation inhibition or degradation), RISC-mediated gene silencing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 512-2 (miR-512-2).